{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:56:44Z","timestamp":1794488204341,"version":"4.9.1"},"reference-count":25,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The diagnosis of germline predisposition to myeloid neoplasms (MN) secondary to DDX41 variants is currently hindered by the long latency period, variable family histories and the frequent occurrence of DDX41 variants of uncertain significance (VUS). We reviewed 4,524 consecutive patients who underwent targeted sequencing for suspected or known MN and analyzed the clinical impact and relevance of DDX41VUS in comparison to DDX41path variants. Among 107 patients (44 [0.9%] DDX41path and 63 DDX41VUS [1.4%; 11 patients with both DDX41path and DDX41VUS]), we identified 17 unique DDX41path and 45 DDX41VUS variants: 24 (23%) and 77 (72%) patients had proven and presumed germline DDX41 variants, respectively. The median age was similar between DDX41path and DDX41VUS (66 vs. 62 years; P=0.41). The median variant allele frequency (VAF) (47% vs. 48%; P=0.62), frequency of somatic myeloid co-mutations (34% vs 25%; P= 0.28), cytogenetic abnormalities (16% vs. 12%; P=&gt;0.99) and family history of hematological malignancies (20% vs. 33%; P=0.59) were comparable between the two groups. Time to treatment in months (1.53 vs. 0.3; P=0.16) and proportion of patients progressing to acute myeloid leukemia (14% vs. 11%; P=0.68), were similar. The median overall survival in patients with high-risk myelodysplastic syndrome\/acute myloid leukemia was 63.4 and 55.7 months in the context of DDX41path and DDX41VUS, respectively (P=0.93). Comparable molecular profiles and clinical outcomes among DDX41path and DDX41VUS patients highlights the need for a comprehensive DDX41 variant interrogation\/classification system, to improve surveillance and management strategies in patients and families with germline DDX41 predisposition syndromes.<\/jats:p>","DOI":"10.3324\/haematol.2023.282867","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:53:33Z","timestamp":1684403613000},"page":"3033-3043","source":"Crossref","is-referenced-by-count":21,"title":["Clinical and molecular correlates of somatic and germline &lt;i&gt;DDX41&lt;\/i&gt; variants in patients and families with myeloid neoplasms"],"prefix":"10.3324","volume":"108","author":[{"given":"Talha","family":"Badar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nanaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viswanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Ongie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Chlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"53734","doi-asserted-by":"crossref","unstructured":"Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia - a review. Br J Haematol. 2008; 140(2):123-132.","DOI":"10.1111\/j.1365-2141.2007.06909.x"},{"key":"53735","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"53736","doi-asserted-by":"crossref","unstructured":"Maciejewski JP, Padgett RA, Brown AL, M\u00fcller-Tidow C. DDX41-related myeloid neoplasia. Semin Hematol. 2017; 54(2):94-97.","DOI":"10.1053\/j.seminhematol.2017.04.007"},{"key":"53737","doi-asserted-by":"crossref","unstructured":"Omura H, Oikawa D, Nakane T. Structural and functional analysis of DDX41: a bispecific immune receptor for DNA and cyclic dinucleotide. Sci Rep. 2016; 6:34756.","DOI":"10.1038\/srep34756"},{"key":"53738","doi-asserted-by":"crossref","unstructured":"Badar T, Chlon T. Germline and somatic defects in DDX41 and its impact on myeloid neoplasms. Curr Hematol Malig Rep. 2022; 17(5):113-120.","DOI":"10.1007\/s11899-022-00667-3"},{"key":"53739","doi-asserted-by":"crossref","unstructured":"Chlon TM, Stepanchick E, Hershberger CE. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021; 28(11):1966-1981.","DOI":"10.1016\/j.stem.2021.08.004"},{"key":"53740","doi-asserted-by":"crossref","unstructured":"Polprasert C, Schulze I, Sekeres MA. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015; 27(5):658-670.","DOI":"10.1016\/j.ccell.2015.03.017"},{"key":"53741","doi-asserted-by":"crossref","unstructured":"Alkhateeb HB, Nanaa A, Viswanatha D. Genetic features and clinical outcomes of patients with isolated and commutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022; 6(2):528-532.","DOI":"10.1182\/bloodadvances.2021005738"},{"key":"53742","unstructured":"Bernard E, Tuechler H, Greenberg PL. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 2022; 1(7):EVIDoa2200008."},{"key":"53743","doi-asserted-by":"crossref","unstructured":"S\u00e9bert M, Passet M, Raimbault A. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019; 134(17):1441-1444.","DOI":"10.1182\/blood.2019000909"},{"key":"53744","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-424.","DOI":"10.1038\/gim.2015.30"},{"key":"53745","doi-asserted-by":"crossref","unstructured":"Li P, Brown S, Williams M. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022; 140(7):716-755.","DOI":"10.1182\/blood.2021015135"},{"key":"53746","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"53747","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"53748","doi-asserted-by":"crossref","unstructured":"Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-425.","DOI":"10.1182\/blood-2005-10-4149"},{"key":"53749","doi-asserted-by":"crossref","unstructured":"St Martin EC, Ferrer A, Wudhikarn K. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol. 2021; 96(9):E327-E330.","DOI":"10.1002\/ajh.26250"},{"key":"53750","doi-asserted-by":"crossref","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016; 99(4):877-885.","DOI":"10.1016\/j.ajhg.2016.08.016"},{"key":"53751","doi-asserted-by":"crossref","unstructured":"Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice-improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Med. 2021; 13(1):31.","DOI":"10.1186\/s13073-021-00835-9"},{"key":"53752","doi-asserted-by":"crossref","unstructured":"Li P, White T, Xie W. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia. 2021; 36(3):664-674.","DOI":"10.1038\/s41375-021-01404-0"},{"key":"53753","doi-asserted-by":"crossref","unstructured":"Alkhateeb HB, Nanaa A, Viswanatha DS. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022; 6(2):528-532.","DOI":"10.1182\/bloodadvances.2021005738"},{"key":"53754","doi-asserted-by":"crossref","unstructured":"Wan Z, Han B. Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data. Ther Adv Hematol. 2021; 12:20406207211032433.","DOI":"10.1177\/20406207211032433"},{"key":"53755","doi-asserted-by":"crossref","unstructured":"Lewinsohn M, Brown AL, Weinel LM. Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood. 2016; 127(8):1017-1023.","DOI":"10.1182\/blood-2015-10-676098"},{"key":"53756","doi-asserted-by":"crossref","unstructured":"Quesada AE, Routbort MJ, DiNardo CD. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019; 94(7):757-766.","DOI":"10.1002\/ajh.25486"},{"key":"53757","doi-asserted-by":"crossref","unstructured":"Makishima H, Saiki R, Nannya Y. Germline DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023; 141(5):534-549.","DOI":"10.1182\/blood.2022018221"},{"key":"53758","doi-asserted-by":"crossref","unstructured":"Duployez N, Largeaud L, Duchmann M. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022; 140(7):756-768.","DOI":"10.1182\/blood.2021015328"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282867\/75621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282867\/76225","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11086\/75621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:07Z","timestamp":1794045847000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282867","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}